Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Diagnostics › Molecular Diagnostics › BioMerieux, Banyan Biomarkers Partner to Commercialize TBI Test

BioMerieux, Banyan Biomarkers Partner to Commercialize TBI Test

Jan 19, 2017
|
staff reporter

NEW YORK (360Dx) – BioMérieux said today it has signed a deal to commercialize Banyan Biomarkers' tests for diagnosing traumatic brain injuries (TBI).

Under the terms of the agreement, BioMérieux will make a $7 million equity investment in Banyan in exchange for rights to commercialize Banyan's TBI tests for global use as in vitro diagnostics on BioMérieux's VIDAS immunoassay platform.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

What's Popular?

In Molecular Diagnostics

  1. Jonathan Rothberg-Led Startup Looks to Bring Disposable POC SARS-CoV-2 Test to Market

    Premium

  2. JP Morgan Healthcare Conference 2021, Day One: Roche, Guardant, Hologic, Thermo Fisher, and More

  3. Report Details COVID-19 Testing Within Federal Government

  4. JP Morgan Healthcare Conference, Day 3: Exact Sciences, Luminex, Danaher, Siemens Healthineers, and More

  5. At JP Morgan Conference, Quidel CEO Discusses Plan to Enter OTC Infectious Disease Test Market

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.